Alembic Pharmaceuticals Ltd Q1 FY2023 Concall Summary

Key Takeaways

• US reset hits hard: US revenue fell to \$47 mn from a ~\$70 mn Q4 peak, driven by a logistics vendor switch that pulled purchases forward and ongoing double-digit price erosion.
• India is the bright spot: Ex-COVID adjusted growth was 20%, with veterinary up ~35%, and management is confident of market-beating growth as investments ramp up.
• Aleor write-off continues to sting: A further ₹115 crores was charged to the P&L, following ₹189 crores in March, reflecting the harsh reality of the US generic market.
• Margins are under siege from all sides: Gross margins fell to 70% from 73-74% on US price erosion and high input costs, with new facility expenses set to add further pressure.
• What to watch next quarter: Whether the US base business stabilizes near the guided \$50 mn run-rate, the pace of India's investment-led growth, and any progress on the F3 facility remediation.

US Business: The Core Problem

• Logistics switch caused a one-time air pocket: A change in the third-party logistics vendor led buyers to pull inventory into Q4 FY22, creating an artificially strong prior quarter and a weak Q1 FY23 as offtake slowed.
• Price erosion is structural, not cyclical: Management sees low-double-digit erosion across the board, driven by oversupply, especially from India, affecting both chronic and acute products.
• Base business run-rate reset lower: The new quarterly base is guided to \$50 mn, down from prior expectations, reflecting a market that has eroded further than anticipated at the end of Q4.
• Peak margins were always unsustainable: US gross margins once exceeded 75% on the back of specific products; management had flagged this as temporary, and the normalization is now playing out.
• Long-term optimism rests on volume: The strategy is to launch 15-18 products annually and consolidate market share in existing products, betting that volume can offset price declines over time.

Pranav Amin: "The near term will remain challenging, but long term we still remain optimistic about the US business."

India Business: The Growth Engine

• Strong underlying performance masked by base effects: Reported topline was distorted by last year's COVID-driven Azithromycin sales; excluding this, Alembic grew +12% against an industry decline of -1%.
• Veterinary is a standout: The segment grew ~35%, signaling a successful diversification beyond the core branded generics portfolio.
• Investment cycle has begun: The company started increasing India investments from Q4 FY22, with a significant ramp-up in Q1, and expects these to translate into topline growth from Q2 and Q3.
• Monsoon tailwind: A strong and well-distributed monsoon through June-August is expected to support the acute portfolio, a key driver for the India business.

Aleor & R&D: The Write-off Fallout

• Aleor intangible written down to near-zero: A ₹115 crores charge in Q1 FY23 follows ₹189 crores in March 2022, leaving residual intangible assets at just ~₹40 crores from a total spend of ~₹350 crores over 3-4 years.
• The write-off is a verdict on the US market: Management explicitly linked the charge to adverse market conditions in the US generic space, signaling that the Aleor pipeline's expected returns have materially diminished.
• Merger in process: Alembic acquired the balance 40% stake in March 2022, making Aleor a 100% subsidiary, and the merger with the parent is now with the NCLT.
• R&D spend to be contained, not cut: Absolute R&D will stay within ₹650-700 crores annually, but management is actively rationalizing spend, evaluating other territories and verticals beyond oral solids given lower US returns.

R. K. Baheti: "You are right, but I look at percentage of turnover as just a consequential number, but in absolute terms, we don't plan to increase R&D."

Margins: Pressure from All Sides

• Gross margin compression is multi-factorial: The 300-400 bps drop to 70% reflects US price erosion, high input costs from elevated crude prices, and a multi-time increase in freight costs across the board.
• Cost control has limited power: Management is doing "everything under the sun" on controllable expenses, but freight and input costs are external, and US realizations are the real swing factor for margin recovery.
• New facilities will add transitional pain: As F2, F3, and F4 come online, initial revenue will be low while cash expenses (₹180-200 crores) and depreciation (₹150 crores) hit the P&L, creating a near-term margin drag.
• No new US capex cycle: Management confirmed no large new US formulation capex is planned, only incremental or maintenance spend, limiting future fixed-cost buildup.

R. K. Baheti: "Margins would stay under some pressure till the realization from US improve while we are doing everything possible under our control or to do some cost rationalization. They would have only a smaller influence of margin. We would bank on US doing better to further improve the margins."

Facilities & Regulatory Pipeline

• F3 remediation is the critical path item: The injectable facility at Karakhadi is under remediation with consultants appointed; management believes a re-inspection will be required and is providing monthly updates to the FDA.
• F2 injectable audit is a near-term catalyst: The oral solid portion is already approved; injectable filings have been made, which should trigger an FDA audit as the agency increases inspection activity.
• F4 is a back-half story: Filings are made, but management does not expect an FDA inspection this year, pushing any contribution further out.
• Formoterol is a bright spot in the portfolio: The product has captured over 15% market share with less competition, supplied via a CMO, and share is expected to grow as supply chain confidence builds.

Guidance & Commitments

Key Metrics